Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Saeed Taheri, Mohammad Ali Sahraian & Nazila Yousefi. (2019) Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison. Journal of Medical Economics 22:1, pages 71-84.
Read now
Read now
Eva Havrdova, Jeffrey A Cohen, Dana Horakova, Ivana Kovarova & Eva Meluzinova. (2017) Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. Therapeutics and Clinical Risk Management 13, pages 1423-1437.
Read now
Read now
Mark D Willis & Neil P Robertson. (2015) Alemtuzumab for the treatment of multiple sclerosis. Therapeutics and Clinical Risk Management 11, pages 525-534.
Read now
Read now
B. Yamout, R. Alroughani, M. Al-Jumah, R. Goueider, M. Dahdaleh, J. Inshasi, S. Hashem, I. Alsharoqi, M. Sahraian, S. Khoury, Z. Alkawi, S. Koussa, M. Zakaria, J. Al Khaburi, T. Alsaadi & S. Bohlega. (2015) Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS). Current Medical Research and Opinion 31:7, pages 1349-1361.
Read now
Read now
Mark Willis & Neil P Robertson. (2014) Drug safety evaluation of alemtuzumab for multiple sclerosis. Expert Opinion on Drug Safety 13:8, pages 1115-1124.
Read now
Read now
Annika Deiß, Isabel Brecht, Axel Haarmann & Mathias Buttmann. (2013) Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Review of Neurotherapeutics 13:3, pages 313-335.
Read now
Read now
Articles from other publishers (20)
Michał Rudnik, Filip Rolski, Suzana Jordan, Tonja Mertelj, Mara Stellato, Oliver Distler, Przemysław Blyszczuk & Gabriela Kania. (2021) Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis. Arthritis & Rheumatology 73:9, pages 1720-1730.
Crossref
Crossref
Heinz WiendlMatthew CarraroGiancarlo ComiGuillermo IzquierdoHo Jin KimBasil SharrackCarlo TornatoreNadia DaizadehLuke ChungAlan K. JacobsRichard J. HoganLinda V. WychowskiBart Van Wijmeersch. (2020) Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. Neurology Neuroimmunology & Neuroinflammation 7:1.
Crossref
Crossref
Richard Phelps, Jonathan A Winston, Daniel Wynn, Mario Habek, Hans-Peter Hartung, Eva Kubala Havrdová, Glen S Markowitz, David H Margolin, Claudio E Rodriguez, Darren P Baker & Alasdair J Coles. (2019) Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal 25:9, pages 1273-1288.
Crossref
Crossref
Mark D. Willis, Trevor P. Pickersgill, Neil P. Robertson, Richard W. J. Lee, Andrew D. Dick & Ester Carreño. (2016) Alemtuzumab-induced remission of multiple sclerosis-associated uveitis. International Ophthalmology 37:5, pages 1229-1233.
Crossref
Crossref
Diana L Vargas & William R Tyor. (2023) Update on Disease-Modifying Therapies for Multiple Sclerosis. Journal of Investigative Medicine 65:5, pages 883-891.
Crossref
Crossref
Ding Chen, Sara J. Ireland, Gina Remington, Enrique Alvarez, Michael K. Racke, Benjamin Greenberg, Elliot M. Frohman & Nancy L. Monson. (2016) CD40-Mediated NF-κB Activation in B Cells Is Increased in Multiple Sclerosis and Modulated by Therapeutics. The Journal of Immunology 197:11, pages 4257-4265.
Crossref
Crossref
Douglas L. ArnoldElizabeth FisherVesna V. BrinarJeffrey A. CohenAlasdair J. ColesGavin GiovannoniHans-Peter HartungEva HavrdovaKrzysztof W. SelmajMiroslav StojanovicHoward L. WeinerStephen L. LakeDavid H. MargolinDavid R. ThomasMichael A. PanzaraD. Alastair S. Compston. (2016) Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS. Neurology 87:14, pages 1464-1472.
Crossref
Crossref
Mark D. Willis & Neil P. Robertson. (2016) Alemtuzumab for Multiple Sclerosis. Current Neurology and Neuroscience Reports 16:9.
Crossref
Crossref
MD Willis, KE Harding, TP Pickersgill, M Wardle, OR Pearson, NJ Scolding, J Smee & NP Robertson. (2016) Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Multiple Sclerosis Journal 22:9, pages 1215-1223.
Crossref
Crossref
Katja ThomasJudith EiseleFrancisco Alejandro Rodriguez-LealUndine HainkeTjalf Ziemssen. (2016) Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. Neurology Neuroimmunology & Neuroinflammation 3:3.
Crossref
Crossref
R. Alroughani, A. Ashkanani, J. Al-Hashel, R. Khan, A. Thussu, K.J. Alexander, P. Vembu, K. Sharfuddin, S. Lamdhade, J.K. John, S. Alkhashan, M. Abualmelh & S. Al-Shammri. (2016) Consensus recommendations for the diagnosis and treatment of multiple sclerosis in Kuwait. Clinical Neurology and Neurosurgery 143, pages 51-64.
Crossref
Crossref
Eric M. Williamson & Joseph R. Berger. (2015) Infection Risk in Patients on Multiple Sclerosis Therapeutics. CNS Drugs 29:3, pages 229-244.
Crossref
Crossref
Annemarie Weissenbacher, Theresa Hautz, Michael Kimelman, Rupert Oberhuber, Hanno Ulmer, Claudia Bösmüller, Manuel Maglione & Stefan Schneeberger. (2015) Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction. Journal of Immunology Research 2015, pages 1-6.
Crossref
Crossref
Sascha Alvermann, Jürgen H. Faiss, Judith Haas, Frank Hoffmann, Wolfgang Köhler, Roland Martin, Dieter Pöhlau, Sven Schippling & Martin Stangel. 2015. Multiple Sklerose. Multiple Sklerose
267
359
.
Qiong Luo, Yang Sun, Fang-Yuan Gong, Wen Liu, Wei Zheng, Yan Shen, Zi-Chun Hua & Qiang Xu. (2014)
Blocking initial infiltration of pioneer CD8
+
T-cells into the CNS via inhibition of SHP-2 ameliorates experimental autoimmune encephalomyelitis in mice
. British Journal of Pharmacology 171:7, pages 1706-1721.
Crossref
Crossref
Joseph R. Berger. 2014. Neurovirology. Neurovirology
357
376
.
Jiri Kovarik. (2013) From Immunosuppression to Immunomodulation: Current Principles and Future Strategies. Pathobiology 80:6, pages 275-281.
Crossref
Crossref
Robert D. Morgan, John M. O’Callaghan, Simon R. Knight & Peter J. Morris. (2012) Alemtuzumab Induction Therapy in Kidney Transplantation. Transplantation 93:12, pages 1179-1188.
Crossref
Crossref
Barlas Büyüktimkin, Qun Wang, Paul Kiptoo, John M. Stewart, Cory Berkland & Teruna J. Siahaan. (2012) Vaccine-like Controlled-Release Delivery of an Immunomodulating Peptide To Treat Experimental Autoimmune Encephalomyelitis. Molecular Pharmaceutics 9:4, pages 979-985.
Crossref
Crossref
Sachin Kedar & Joseph R. Berger. (2011) The Changing Landscape of Progressive Multifocal Leukoencephalopathy. Current Infectious Disease Reports 13:4, pages 380-386.
Crossref
Crossref